Bristol Myers Squibb Dividend Under Pressure | Business and Finance News

Bristol Myers Squibb’s juicy 4.1% dividend yield looks solid for now, backed by strong earnings and free cash flow—though looming patent expirations for big sellers like Eliquis and Opdivo threaten future revenue. With a promising pipeline stepping in, the dividend remains defendable, even as investors weigh the risk of the looming “patent cliff.” Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/0b1d991b778d3290